{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:56:12Z","timestamp":1790124972822,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005928","name":"Daiwa Securities Health Foundation","doi-asserted-by":"publisher","award":["2809"],"award-info":[{"award-number":["2809"]}],"id":[{"id":"10.13039\/501100005928","id-type":"DOI","asserted-by":"publisher"}]},{"name":"QR Program of Kyushu University","award":["28332"],"award-info":[{"award-number":["28332"]}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes and are becoming a standard treatment for many cancer types. However, these drugs also induce immune-related adverse events, among which interstitial lung disease (ILD) is potentially fatal. The underlying mechanism of ILD induction by ICIs is largely unknown. With the use of flow cytometry, we determined the expression levels of the immune-checkpoint proteins PD-1, TIM-3, TIGIT, LAG-3 and PD-L1 in T cells of bronchoalveolar lavage fluid (BALF) from patients with ICI-related ILD and compared them with those for patients with sarcoidosis or with ILD related to connective tissue disease or cytotoxic drug use. The proportions of CD8+ T cells positive for both PD-1 and TIM-3 or for TIGIT in BALF were significantly higher for ICI-related ILD patients than for those with other types of ILD. A prominent increase in the proportion of PD-1+PD-L1+ cells among CD8+ T cells was also apparent in BALF of a patient with a fatal case of ICI-related ILD, and the proportion of such cells was positively correlated with the grade of ICI-related ILD. Our data reveal the immune-checkpoint profiles of T cells in ICI-related ILD and may provide mechanistic insight into the development of this adverse event.<\/jats:p>","DOI":"10.1093\/intimm\/dxaa022","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T19:11:49Z","timestamp":1585941109000},"page":"547-557","source":"Crossref","is-referenced-by-count":38,"title":["Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease"],"prefix":"10.1093","volume":"32","author":[{"given":"Kunihiro","family":"Suzuki","sequence":"first","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-0631","authenticated-orcid":false,"given":"Toyoshi","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[{"name":"Department of Medicine and Comprehensive Biosystemic Science, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Comprehensive Biosystemic Science, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ikematsu","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Otsubo","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Yoneshima","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Iwama","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Arimura-Omori","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Harada","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University , Maidashi, Higashi-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2022070716464880500_CIT0001","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2022070716464880500_CIT0002","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"2022070716464880500_CIT0003","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"2022070716464880500_CIT0004","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur. Respir. J"},{"key":"2022070716464880500_CIT0005","first-page":"736","article-title":"Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ER","volume":"60","author":"Hunninghake","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"2022070716464880500_CIT0006","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Strek","year":"2015","journal-title":"Eur. Respir. J"},{"key":"2022070716464880500_CIT0007","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"key":"2022070716464880500_CIT0008","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000079633","article-title":"Interstitial lung disease induced by drugs and radiation","volume":"71","author":"Camus","year":"2004","journal-title":"Respiration"},{"key":"2022070716464880500_CIT0009","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jtho.2015.10.004","article-title":"Organizing pneumonia induced by nivolumab in a patient with metastatic melanoma","volume":"11","author":"Nakashima","year":"2016","journal-title":"J. Thorac. Oncol"},{"key":"2022070716464880500_CIT0010","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2169\/internalmedicine.8271-16","article-title":"Nivolumab-induced acute fibrinous and organizing pneumonia (AFOP)","volume":"56","author":"Ishiwata","year":"2017","journal-title":"Intern. Med"},{"key":"2022070716464880500_CIT0011","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"2022070716464880500_CIT0012","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022070716464880500_CIT0013","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1111\/cas.13723","article-title":"PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer","volume":"109","author":"Nakano","year":"2018","journal-title":"Cancer Sci"},{"key":"2022070716464880500_CIT0014","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2326-6066.CIR-15-0266","article-title":"Survival of lung adenocarcinoma patients predicted from expression of PD-L1, galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells","volume":"4","author":"Ohue","year":"2016","journal-title":"Cancer Immunol. Res"},{"key":"2022070716464880500_CIT0015","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/annonc\/mdx214","article-title":"Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment","volume":"28","author":"Yanagihara","year":"2017","journal-title":"Ann. Oncol"},{"key":"2022070716464880500_CIT0016","doi-asserted-by":"crossref","first-page":"30587","DOI":"10.18632\/oncotarget.25743","article-title":"Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade","volume":"9","author":"Tanaka","year":"2018","journal-title":"Oncotarget"},{"key":"2022070716464880500_CIT0017","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"2022070716464880500_CIT0018","doi-asserted-by":"crossref","first-page":"e1386362","DOI":"10.1080\/2162402X.2017.1386362","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"L\u00e4ubli","year":"2018","journal-title":"Oncoimmunology"},{"key":"2022070716464880500_CIT0019","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"2022070716464880500_CIT0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12518","article-title":"TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol. Rev"},{"key":"2022070716464880500_CIT0021","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev"},{"key":"2022070716464880500_CIT0022","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells","volume":"125","author":"Smyth","year":"2015","journal-title":"J. Clin. Invest"},{"key":"2022070716464880500_CIT0023","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"2022070716464880500_CIT0024","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jtho.2017.01.019","article-title":"LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1\/PD-L1 and tumor-infiltrating lymphocytes","volume":"12","author":"He","year":"2017","journal-title":"J. Thorac. Oncol"},{"key":"2022070716464880500_CIT0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.celrep.2018.06.054","article-title":"Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Cell Rep"},{"key":"2022070716464880500_CIT0026","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"2022070716464880500_CIT0027","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00277-017-3146-z","article-title":"Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia\/lymphoma","volume":"97","author":"Yanagihara","year":"2018","journal-title":"Ann. Hematol"},{"key":"2022070716464880500_CIT0028","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev"},{"key":"2022070716464880500_CIT0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-25302-1","article-title":"Egr2-independent, Klf1-mediated induction of PD-L1 in CD4+T cells","volume":"8","author":"Teruya","year":"2018","journal-title":"Sci. Rep"},{"key":"2022070716464880500_CIT0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat. Immunol"},{"key":"2022070716464880500_CIT0031","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Novello","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"2022070716464880500_CIT0032","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"2022070716464880500_CIT0033","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non\u2013small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J. Thorac. Oncol"},{"key":"2022070716464880500_CIT0034","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022070716464880500_CIT0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"}],"container-title":["International Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/intimm\/advance-article-pdf\/doi\/10.1093\/intimm\/dxaa022\/33126739\/dxaa022.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/32\/8\/547\/44565206\/dxaa022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/32\/8\/547\/44565206\/dxaa022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T16:47:30Z","timestamp":1657212450000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/intimm\/article\/32\/8\/547\/5816792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,7,28]]}},"URL":"https:\/\/doi.org\/10.1093\/intimm\/dxaa022","relation":{},"ISSN":["1460-2377"],"issn-type":[{"value":"1460-2377","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,4,7]]}}}